Animal study · mice
Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 days
Checked against the paper Animal studyPublished by PepVault
The takeaway
In mice missing the MC4R pathway, retatrutide still produced sizable weight loss, between semaglutide and tirzepatide in this study, with lean mass lost alongside fat.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2026
- Journal
- Int J Obes (Lond)
What they tested
The team tested whether semaglutide, tirzepatide and retatrutide still cause weight loss in mice lacking MC4R, a brain receptor that helps control eating and body weight, and how the three compare.
How the study was done
An animal study in MC4R knockout mice (mice bred without a working MC4R gene) given semaglutide, tirzepatide or retatrutide for 21 days, with the three drugs compared to each other.

Model. Individual results vary.
What they found
In MC4R knockout mice, body weight fell by 24.1 ± 5.8% with retatrutide, 19.7 ± 4.1% with semaglutide and 31.6 ± 7.6% with tirzepatide. Echo-MRI scans showed all three drugs significantly lowered both fat mass and lean mass. All three improved plasma insulin, HOMA-IR (a measure of insulin resistance), cholesterol and the liver damage markers AST and ALT, and reduced liver enlargement. They lowered genes tied to fatty acid synthesis but had no significant effect on inflammation-related genes. They also reduced energy expenditure, and only tirzepatide significantly lowered the respiratory quotient.
What it doesn’t show
This was a 21-day study in mice, so it isn't a human result and doesn't show what happens in people with MC4R or POMC pathway defects. Lean mass dropped along with fat mass in these mice.
The paper
Hitaka et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. Int J Obes (Lond). 2026.
The compounds
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.